Zyban Articles
UK DoH to investigate Zyban safety
19 February 2001
40%-123% US Rx price variations found
13 February 2001
GSK Australia accused of misleading ads
15 January 2001
Glaxo Wellcome/SmithKline Beecham merger completed at last
3 January 2001
Glaxo Wellcome/SmithKline Beecham merger gets go-ahead from FTC
18 December 2000
Pfizer forecasts strong revenue growth in 2001-2002 at R&D meeting
14 December 2000
GlaxoSmithKline on December 27?
13 December 2000
New work program for NICE announced
20 November 2000
GW hits Impax with bupropion lawsuits
10 October 2000
GW/SB merger delayed until end of year
11 September 2000
GW launches Zyban in the UK
26 June 2000
Copaxone pushes Teva FY profits up 39.3%
16 February 2000
NeuroSearch signs $47m deal with GW
24 January 2000
Glaxo SmithKline, an R&D powerhouse and global number one
17 January 2000
Glaxo Wellcome patent dispute with Andrx
13 September 1999
US DTC Rx ad spend hit $1.3 billion in 1998
25 May 1999
GW files first dossiers for Flixotide in COPD
10 May 1999
Zyban outperforms nicotine patches
5 March 1999
GW files for EU approval of Zyban
3 March 1999
Pfizer's Zyrtec Tops DTC Ad Spending In May
16 September 1998
Canada Approve Zyban
20 August 1998
US Rx DTC Ad Spend Set To Beat $1 Billion Again
28 July 1998
Glaxo Wellcome To Buy Korea's Youngjin
17 July 1998
UK Pharma Leaders Outline Strategy
22 June 1998
Glaxo Wellcome Calls For Injunction On Zyban Information
27 April 1998
Wall Street Notes And FDA Confirms Rapid Drug Pace
23 March 1998
Neutral Rating For GW And SB From MSDW
10 March 1998
Glaxo Wellcome Profits Hit By Strength Of Sterling
19 February 1998
GW-SB Merger Will Create R&D Superpower
5 February 1998
Impact Of Propecia On Merck & Co Assessed
28 January 1998
Underlying Growth Healthy At GW Despite Strong L
6 August 1997
Zyban Cheaper Than Nicotine Replacement
23 July 1997
Upbeat UK Companies At Goldman Sachs Conference
17 June 1997
First Approval, In The USA, For Glaxo's Zyban
26 May 1997
High SSRI Link To Sexual Dysfunction
5 May 1997
Glaxo Wellcome 1996 Product Performance
17 March 1997
GW's Smoking Pills "OKed" In USA
23 December 1996
Medi-Cal Formulary Additions
4 March 1996
Glaxo Wellcome Unveils Revamped Pipeline
20 November 1995
Glaxo, Wellcome Product Lines Are Complementary
6 February 1995
Do Wellcome Results Justify Higher Bid
6 February 1995
Serzone Priced At Discount To SSRIs In USA
16 January 1995
Wellbutrin And Smoking Cessation
28 November 1994
WELLCOME R&D PIPELINE: PART 2
17 May 1993
HHS RECOMMENDATIONS FOR ANTIDEPRESSANTS
3 May 1993
WELLCOME'S US "TIDAL WAVE" REVERSING?
21 December 1992
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
